Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Aug;23(8):1256-1263.
doi: 10.1016/j.ajt.2023.04.028. Epub 2023 May 6.

Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multicenter study

Kaushik Amancherla  1 , Kelly H Schlendorf  2 , Caitlyn Vlasschaert  3 , Brandon D Lowery  4 , Quinn S Wells  5 , Sarah B See  6 , Emmanuel Zorn  6 , Paolo C Colombo  7 , Muredach P Reilly  7 , JoAnn Lindenfeld  2 , Nir Uriel  7 , Jane E Freedman  2 , Ravi V Shah  2 , Javid Moslehi  8 , Alexander G Bick  9 , Kevin Clerkin  7
Affiliations
Multicenter Study

Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multicenter study

Kaushik Amancherla et al. Am J Transplant. 2023 Aug.

Abstract

Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature, with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and posttransplant outcomes, including CAV. We analyzed 479 HT recipients with stored DNA samples at 2 high-volume transplant centers, Vanderbilt University Medical Center and Columbia University Irving Medical Center. We explored the association between the presence of CHIP mutations with CAV and mortality after HT. In this case-control analysis, carriers of CHIP mutations were not at increased risk of CAV or mortality after HT. In a large multicenter genomics study of the heart transplant population, the presence of CHIP mutations was not associated with an increased risk of CAV or posttransplant mortality.

Keywords: CHIP; cardiac allograft vasculopathy; clonal hematopoiesis of indeterminate potential; heart transplant; transplant genomics.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alexander G Bick reports a relationship with TenSixteen Bio that includes: consulting or advisory. Javid Moslehi reports a relationship with Bristol Myers Squibb, AstraZeneca, Myovant, Cytokinetics, Takeda, BeiGene, Kiniksa, Kurome Therapeutics, and Pfizer that includes: consulting or advisory.

Figures

Figure 1.
Figure 1.
The distribution of CHIP mutations across both VUMC and CUIMC cohorts.
Figure 2.
Figure 2.
Kaplan-Meier survival estimates by CHIP status in the VUMC cohort. Time is defined in days post-transplant.
See this image and copyright information in PMC

References

    1. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Jr., Hsich E, Meiser B, Potena L, Robinson A, Rossano JW, Sadavarte A, Singh TP, Zuckermann A, Stehlik J, International Society for H and Lung T. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant 2019;38:1056–1066. - PMC - PubMed
    1. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, Madsen J, Parameshwar J, Starling RC and Uber PA. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010;29:717–27. - PubMed
    1. Pober JS, Jane-wit D, Qin L and Tellides G. Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy. Arterioscler Thromb Vasc Biol 2014;34:1609–14. - PMC - PubMed
    1. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S and Ebert BL. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med 2017;377:111–121. - PMC - PubMed
    1. Midic D, Rinke J, Perner F, Muller V, Hinze A, Pester F, Landschulze J, Ernst J, Gruhn B, Matziolis G, Heidel FH, Hochhaus A and Ernst T. Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. Leukemia 2020;34:2198–2205. - PMC - PubMed

Publication types